» Articles » PMID: 22925812

Neutrophil-lymphocyte Ratio Reflects Hepatocellular Carcinoma Recurrence After Liver Transplantation Via Inflammatory Microenvironment

Overview
Journal J Hepatol
Publisher Elsevier
Specialty Gastroenterology
Date 2012 Aug 29
PMID 22925812
Citations 229
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Although the Milan criteria (MC) have been used to select liver transplantation candidates among patients with hepatocellular carcinoma (HCC), many patients exceeding the MC have shown good prognosis. Preoperative neutrophil-lymphocyte ratio (NLR) is a predictor of patient prognosis, but its mechanism has never been clarified.

Methods: We assessed outcomes in 158 patients who had undergone living-donor liver transplantation (LDLT) for HCC. Recurrence-free survival (RFS) was determined in patients with high (≥ 4) and low (<4) NLR. Levels of expression of vascular endothelial growth factor (VEGF), interleukin (IL)-8, IL-17, CD68, and CD163 were measured.

Results: The 5-year RFS rate was significantly lower in patients with high (n=26) than with low (n=132) NLR (30.3% vs. 89.0%, p<0.0001), in patients with high (n=15) than with low (n=79) NLR who met the MC (73.6% vs. 100%, p=0.0008) and in patients with high (n=11) than with low (n=53) NLR who exceeded the MC (0% vs. 76.1%, p=0.0002). Tumor expression of VEGF, IL8, IL-17, CD68, and CD163 was similar in the high and low NLR groups, but serum and peritumoral IL-17 levels were significantly higher in the high-NLR group (p=0.01 each). The density of peritumoral CD163 correlated with the density of peritumoral IL-17-producing cells (p=0.04) and was significantly higher in the high-NLR group (p=0.005).

Conclusions: NLR predicts outcomes after LDLT for HCC via the inflammatory tumor microenvironment. Combined with the MC, NLR may be a new criterion for LDLT candidates with HCC.

Citing Articles

The prognostic value of systemic immune-inflammation index in patients with unresectable hepatocellular carcinoma treated with immune-based therapy.

He T, Xu B, Wang L, Wang Z, Shi H, Zhong C Biomark Res. 2025; 13(1):10.

PMID: 39806475 PMC: 11730499. DOI: 10.1186/s40364-024-00722-6.


Predictive value of neutrophil-to-lymphocyte ratio and MELD score for short-term survival of patients with HBV-DeCi.

Han Z, Qi L, Chen S, Zhang J, Guo X, Liang C Biomark Med. 2025; 19(2):43-49.

PMID: 39781609 PMC: 11749384. DOI: 10.1080/17520363.2024.2448112.


Evaluating body roundness index and systemic immune inflammation index for mortality prediction in MAFLD patients.

Zeng D, Zeng Q, Li S, Lu J, Cheng N Sci Rep. 2025; 15(1):330.

PMID: 39747385 PMC: 11695853. DOI: 10.1038/s41598-024-83324-4.


Real-world experience of lenvatinib-based therapy in patients with advanced hepatocellular carcinoma.

Wang H, Lai H, Su W, Kao J, Hsu W, Chen H J Gastrointest Oncol. 2024; 15(5):2216-2229.

PMID: 39554567 PMC: 11565097. DOI: 10.21037/jgo-24-351.


Oral Mucositis in Adult Cancer Patients Undergoing Chemotherapy: Six-Month On-Treatment Follow-Up.

Padure A, Horhat R, Talpos-Niculescu I, Scheusan R, Anghel M, Rusu L J Clin Med. 2024; 13(19).

PMID: 39407783 PMC: 11477337. DOI: 10.3390/jcm13195723.